Declaration of Un-audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026

Mangalam Drugs and Organics Limited Regd: Office : Rupam Building, 3rd Floor, 239 P. D’Mello Road, Near G. P. 0. Mumbai - 400 001 ® 91-22-62616200/ 6300 / 8787 @ 91-22-62619090 @ CIN : L24230MH1972PLC 116413 REF: MDOL/CS-SE/2026- 27/021 August 12,2026 Listing Department Listing Department BSE Ltd National Stock Exchange of India Limited 15t Floor, New Trade Wing, “Exchange Plaza”, 5t Floor, Phiroze Jeejeebhoy Towers, Plot No. C-1, Block G, Dalal Street, Fort, Bandra - Kurla Complex, Mumbai - 400 001. Bandra(E), Mumbai - 400 051 Scrip Code: 532637 Symbol: MANGALAM Sub: Qutcome e Meeting held on Wed ay, August 12, 20 Ref: Regulatiol read with Schedule III of th BI (Listing Obligati and Disclosure uirements) Regulations, 201 EBI LODR Regulations) read with SEBI Circular CIR MD 201 mber Dear Sir / Madam, With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today ie. Wednesday, August 12, 2026 has inter-alia transacted, considered and approved the following business: 1. The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended June 30, 2026 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure 1.) 2. Appointment of M/s L.N. Joshi & Co. Practicing Company Secretaries (CP No.: 4216), as Secretarial Auditors of the Company in line with SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, for a period of five consecutive years commencing from conclusion of 53rd AGM to 58t AGM of the Company, subject to approval of the members at the ensuing AGM. 3. Approved appointment of M/s SN. Nanda & Co, Chartered Accountants (FRN:000685N) as the Statutory Auditors of the Company, for a term of five consecutive years, commencing from the conclusion of the 534 AGM till the conclusion of the 58t AGM, subject to the approval of the shareholders at the ensuing AGM. Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com Mangalam Drugs and Organics Limited MANGALAM Regd: Office : Rupam Building, 3rd Floor, 239 P. D’Mello Road, NearG. P. 0. Mumbai - 400 001 ' ® 91-22-62/6 613060 2/ 807087 @ 91-22-62619090 o CIN : (24230MH1972P1C116413 oy ¥ Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, the statutory Auditors have not expressed any modified opinion(s) in their Limited Review Reports. The Board meeting commenced at 12:30 P.M. and concluded at 3: 40 P.M. We request you to take the same on your records. Thanking You, Yours faithfully, oFor Manygalam D rugs & Organics Limited vardhan M. Dhoot Chairman & Managing Directo! DIN: 01240086 Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com UNIT NO.127, 15T FLOOR, V s. SOMANI & CO. PRABHADEVI UNIQUE INDUSTRIAL CHARTERED ACCOUNTANTS PREMISES CO-OP SOCIETY LTD., TWIN TOWER LANE, OFF. VEER SAVARKAR MARG, PRABHADEVI, MUMBAI 400 025. PHONE NO: 022 66624558 EMAIL ID: vidyadhar@cavssomani.com Limited Review Report on Unaudited Standalone Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 30™ June, 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Sccurities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10" August 2021 as amended. The Board ofD irectors, Mangalam Drugs and Organics Limited, 1. We have reviewed the accompanying statement of Standalone unaudited financial results (the "Statement") of Mangalam Drugs and Organics Limited (the "Company") for the quarter ended 30" June 2026 attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015, as amended (the "Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the requirement of recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“ Listing Regulations”) as prescribed in Securities and Exchange Board ofI ndia operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that ""‘X t be identified in an audit. Accordingly, we do not express an audit opinion V. 5. SOMANI & CO. Chartered Accountants 4, Conclusion Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘'Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For V.S. SOMANI & Co., Chartered Accountants Proprietor Place: Mumbai Date: August 12", 2026 M Ue Dm Ib Ne r Ns ohi .p 2No 4. J1 o02 26 .64 6 64LXoVN 03273 MANGALAM DRUGS AND ORGANICS LIMITED CIN - L24230MH1972PLC116413 Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.0, Mumbai - 400 001. Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026 (Rs. In Lakhs) Quarter Ended Year Ended Sr.No| Particulars 30.06.2026 | 31.03.2026 | 30.06.2025 | 31.03.2026 Unaudited | _Audited | Unaudited | Audited (a) Revenue from Operations 5711.93 6.728.71 572087 | 2321327 (b) Other Income 1147 894 14.04 7631 Total Income (net) (a+b) 5.723.10 ©,737.65 5734.91 23,289.58 2 |Expenses (a) Cost of Materials Consumed 3,359.45 3,551.08 2333.37 12,479.22 (b) Purchase of Stock in trade - - - - (c) Changes in Inventories of Finished Goods, Work In Progress and Stock-in-trade (@422)| 116517 1,624.53 3,208.35 (d) Employee Benefits Expenses 882.37 817.76 931.25 334617 (e) Finance costs (net) 367.53 308.24 404.45 1,620.82 () Depreciation and amortization expenses 399.02 456.29 438.09 1,784.34 (g) Other Expenses 1,425.04 1,730.48 1,296.02 5,649.42 Total Expenses (a to g) 6,389.19 8,029.02 7,027.71 28,088.32 3 [Profit/ (Los [Showing first 8,000 characters — download PDF for full document]